Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

This is a clinical practice guideline for patients with stage IV non-small-cell lung cancer (NSCLC). The guideline provides recommendations on systemic therapy options for NSCLC such as standard chemotherapy, immune checkpoint therapy, antibody therapy and other drug classes and treatment settings. Outcomes of interest include therapeutic efficacy, adverse effects, overall survival and quality of life. The guideline also discusses health disparities and multiple chronic conditions and provides recommendations on managing these barriers.